Search Within

David Hyman

  1. "Maria Arcila"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (24)
Groups
  1. Department of Medicine (57)
  2. Department of Pathology and Laboratory Medicine (57)
  3. Early Drug Development Service (57)
  4. Solid Tumor Oncology Division (57)
  5. GSK Faculty (55)
  6. Human Oncology and Pathogenesis Program (49)

More Groups

People
  1. Maria Arcila (57)
  2. Michael Berger (41)
  3. Marc Ladanyi (38)
  4. David Solit (36)
  5. Ahmet Zehir (35)
  6. Jose Baselga (23)

More People

Years
  1. 2020 (4)
  2. 2019 (6)
  3. 2018 (8)
  4. 2017 (15)
  5. 2016 (7)
  6. 2015 (16)

More Years

Publications
  1. Journal of Clinical Oncology (17)
  2. Blood (6)
  3. Cancer Discovery (4)
  4. Cancer Research (3)
  5. Clinical Cancer Research (3)
  6. JAMA Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (18)
  2. American Association for Cancer Research (11)
  3. American Society of Hematology (6)
  4. Nature Publishing Group (6)
  5. American Medical Association (4)
  6. Nature Research (3)

More Publishers

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay
    Meeting Abstract

    Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Genomic characterization of primary and metastatic prostate cancer (PC) using a targeted next-generation sequencing assay
    Meeting Abstract

    Abida, W.; Curtis, K. R.; Taylor, B. S.; Arcila, M. E.; Brennan, R.; Danila, D. C.; Rathkopf, D. E.; Morris, M. J.; Slovin, S. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comparison of genetic alterations from the bladder cancer genome atlas (TCGA) and a prospective set of high-grade urothelial carcinoma tumors using a CLIA laboratory next generation sequencing assay
    Meeting Abstract

    Iyer, G.; Bagrodia, A.; Cha, E. K.; Boyd, M. E.; Zehir, A.; Cheng, D. T.; Hyman, D. M.; Bambury, R. M.; Arcila, M. E.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of RAS/RAF mutation status and identification of alternative targetable driver alterations in RAS/RAF wild type colorectal carcinoma using a hybrid capture-based next-generation sequencing assay
    Meeting Abstract

    Hechtman, J.; Zehir, A.; Cheng, D.; Shia, J. R.; Solit, D.; Yaeger, R.; Hyman, D.; Arcila, M.; Berger, M.; Ladanyi, M.; more...
    Modern Pathology (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of RAS/RAF mutation status and identification of alternative targetable driver alterations in RAS/RAF wild type colorectal carcinoma using a hybrid capture-based next-generation sequencing assay
    Meeting Abstract

    Hechtman, J.; Zehir, A.; Cheng, D.; Shia, J.; Solit, D.; Yaeger, R.; Hyman, D.; Arcila, M.; Berger, M.; Ladanyi, M.; more...
    Laboratory Investigation (2015)

    Fulltext@MSK | Save
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
    Journal Article

    Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
    Meeting Abstract

    Hyman, D. M.; Diamond, E.; Vibat, C. R.; Hassaine, L.; Poole, J.; Patel, M.; Holley, V.; Cabrilo, G.; Lu, T. T.; Arcila, M.; more...
    Blood (2014)

    Fulltext@MSK | Save